Product Description
Praziquantel is the drug of choice for the treatment of all forms of schistosomiasis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12811543/)
Mechanisms of Action: Calcium Channel Opener
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Cyprus | Czech | Egypt | European Medicines Agency | France | Germany | Greece | Hong Kong | India | Jordan | Korea | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/07/2024 |
News Article |
Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose |
|
12/18/2023 |
News Article |
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children |
|
09/08/2023 |
News Article |
Praziquantel Market Size, Regional Status and Outlook 2023-2030 |
|
09/05/2023 |
News Article |
Drugs For Schistosomiasis Market Research Report 2023-2030, 110 Pages Report |